亚砷酸联合吉西他滨和顺铂治疗难治性或复发性非霍奇金淋巴瘤

目的：观察亚砷酸注射液（三氧化二砷，As2O3）联合吉西他滨和顺铂方案治疗难治性或复发性非霍奇金淋巴瘤（NHL）的有效率。方法：18例难治性或复发性NHL患者，男性12例，女性6例，中位年龄51岁。给予As2O3注射液10mg／d静脉滴注第1—14天，吉西他滨1000mg／m^2，第1和第8天，顺铂25mg／m^2第1—3天，21d为1个周期。结果：18例患者中完全缓解4例，部分缓解7例，有效率61．1％。肿瘤中位进展时间（TTP）6．5个月，1年生存率42．3％。不良反应主要为血液学毒性、肝肾功能损害。结论：亚砷酸注射液联合吉西他滨和顺铂方案是治疗复发或难治性非霍奇金淋巴瘤较为安全、有效的化疗方案。

Arsenious oxide and gemcitabine plus cisplatin in the treatment of patients with relapsed or refractory non -Hodgkins lymphoma

Objective：To evaluate the efficacy of a combination of arsenious oxide and gemcitabine plus cisplatin in patients with relapsed or refractory non -Hedgkin＇s lymphoma. Methods. Eighteen patients （1：2 males and 6 females） with relapsed or refractory NHL were observed, patients were treated by gemcitabine 1000mg/m^2 on dl.sand cisplatin 25mg/m^2 on d1-3. Arsenious oxide 10mg/d infusion,from the first to 14 day,repeated every 21 days. Ressults：Of 18 assessable patients, over all response rate was 61.1%, including 4 complete response and 7 patial response. Median time to progression was 6.5 months, and I year survival rate was 42.3% . Toxicity mainly included mylosuppreasion,hepatorenal dysfunction. Conclusion： Arsenious oxide and gemcitabine plus cisplatin chemotherpy regimen is safe and effective for patients with relapsed or refractory non - Hodgkin＇s lymphoma.